Rep. Doris Matsui (D-CA) today introduced an AHA-supported bill that would make changes to the 340B drug savings program, including overturning last year’s significant Medicare payment reduction for many hospitals in the program and adding program integrity requirements for drug manufacturers participating in the program. “Hospitals and clinics doing life-saving work rely on the 340B program to help them provide inclusive and affordable care in their communities,” Matsui said. “This legislation makes clear the importance of preserving the program so safety net providers can continue to serve low-income and vulnerable patients, while expanding it to help address the opioid crisis.” Specifically, the Stretching Entity Resources for Vulnerable (SERV) Communities Act would overturn the nearly 30% Medicare payment cut that went into effect Jan. 1 for certain hospitals for outpatient drugs purchased under the 340B program. Among other provisions, the bill would require implementation of the long delayed 340B ceiling price calculation methodology and application of civil monetary penalties for manufacturers’ violations of the ceiling price.

Headline
As published April 20, the Department of Justice released an interim final rule in the Federal Register to delay compliance dates for states and local…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The AHA today released its Health Care Plan Accountability Update, covering the latest developments in Medicare Advantage, legislation and…
Headline
UnitedHealth Group announced plans to expand its Rural Payment Acceleration Pilot to reduce Medicare Advantage payment processing times for…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…